Deactivating COVID-19 on Footwear

New Study Show UVC Technology Deactivates COVID-19 on Footwear

Researchers have proven a device using ultraviolet light technology can neutralize the COVID-19 virus and other infectious diseases on the soles of shoes by more than 99.5 percent, according to a new study.

The device, called HealthySole® PLUS, is being introduced in hospitals and other settings where infection control is urgent. A home version of the device (HealthySole® HOME) is also available.

“The device deactivated coronavirus markers by over 99.5 percent versus the control across three separate tests,” according to the report as published by CREM Co, an internationally recognized infectious disease research and testing organization based near Toronto, Canada.

As hospitals seek ways to reduce COVID-19 infections, a recent Center for Disease Control (CDC) report points out that the virus is spread through floors and foot traffic, and not just by person-to-person contact.

“As people walk, they not only collect and spread pathogens on the soles of their shoes, but also aerosolize the virus, essentially kicking it back up in the air,” said HealthySole CEO Nelson Patterson. “The HealthySole device helps ensure pathogens aren’t tracked from patient rooms or wards to other locations. Preventing pathogen spread is critical for hospitals and other facilities, such as police stations with close quarters and high foot traffic, too.”

CDC Cites Wuhan Study on COVID-19 Spread in Hospitals

Research published April 10 by the CDC found that floors and shoe soles had the highest concentrations of COVID-19 in samples taken at a hospital facility in Wuhan, China. It also found the virus was being tracked well beyond patient rooms to other parts of the hospital, including into non-patient care areas such as hospital pharmacies where sampling indicated a 100 percent COVID-19 presence.

The study strongly recommended that “persons disinfect shoe soles before walking out of wards containing COVID-19 patients.”

While hospitals often scrub floors daily with a variety of cleaning agents, these steps provide only a temporary solution. As soon as someone walks on the cleaned floors with infected shoes, floors are rapidly re-contaminated, sometimes in as little as 30 minutes.

Prior research on one of the most difficult to control hospital pathogens, C. difficile, conducted at Children’s Hospital at Erlanger by the University of Tennessee College of Medicine at Chattanooga found UVC light exposure to shoe soles to be statistically beneficial with an overall average decrease of 28 percent for the number of positive swabs per room.

“These studies clearly show that infection prevention must move beyond the traditional single-minded focus on hand washing and reliance on personal protective equipment (PPEs),” Patterson said. “We have to look at our shoe soles – where we’ve been and where we’re going. Fortunately, UVC technology is offering a solution.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”